Biomarkers reveal vital insights that could improve treatment strategies for aggressive prostate cancer, offering hope for ...

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical ...

THOUSANDS more men should receive an existing prostate cancer drug on the NHS as research shows it could halve their death ...

The test could help direct prostate cancer patients to the best treatment option for them, researchers behind the findings ...

Exosomes transform prostate cancer care with early detection, tailored treatments, and real-time prognosis tracking for ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...

New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while ...

AI could bring an end to the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, ...

A postcode lottery means the £77-a-month drug is available to certain patients in Scotland and Wales, but not in England.